A second Phase 3 trial of ensifentrine, a candidate product for chronic obstructive pulmonary disease (COPD), has met its primary endpoint, paving the way for a regulatory submission in the US in the first half of 2023, the developer Verona Pharma Plc announced on 20 December. Ensifentrine is a dual inhibitor of the enzymes phosphodiesterase 3 and 4, a mode of action that enables it to combine both bronchodilator and anti-inflammatory effects in a single compound.
